Senior Correspondent, London
Ben's Feed
Feb 1, 2015
Feb 1, 2015
Feb 1, 2015

Analysis: In pursuit of next-generation Ebola stockpile vaccines

LONDON (Reuters) – As West Africa’s devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.

Determined not to lose scientific momentum that could make the world’s first effective Ebola interventions a reality, researchers say the shots, as well as being proven to work, must be cheap, easy to handle in Africa and able to hit multiple virus strains.

Feb 1, 2015

In pursuit of next-generation Ebola stockpile vaccines

LONDON (Reuters) – As West Africa’s devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.

Determined not to lose scientific momentum that could make the world’s first effective Ebola interventions a reality, researchers say the shots, as well as being proven to work, must be cheap, easy to handle in Africa and able to hit multiple virus strains.

Jan 30, 2015
Jan 30, 2015

UK to launch 100,000 genomes project as Obama backs DNA drive

LONDON, Jan 30 (Reuters) – Gene research is getting a boost
on both sides of the Atlantic, with scientists in England set to
launch a project on Feb. 2 to analyse 100,000 entire human
genomes and U.S. President Barack Obama backing a big new DNA
data drive.

The twin projects show the accelerating work by researchers
to understand the underlying basis of diseases and develop
medicines targeted to the genetic profile of individual
patients.

Jan 30, 2015
Jan 30, 2015
Jan 29, 2015
Jan 29, 2015

Stoppard’s new play lifts the lid on brain science

LONDON, Jan 29 (Reuters) – Tom Stoppard, the grand old man
of British theatre, is back with his first new stage play in
nine years, tackling typically big ideas: consciousness, science
and God.

“The Hard Problem” is a 100-minute gallop, with no interval,
through neurobiology, religion and improbable “black swan”
events in financial markets that is both contemporary and
timeless. Along the way there are tales of altruistic vampire
bats and some good jokes.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben